Carisma Therapeutics (CARM) Expected to Announce Earnings on Monday

Posted by Nicole Kennedy on Mar 25th, 2026

Carisma Therapeutics (NASDAQ:CARM – Get Free Report) is expected to post its resultson Monday, March 30th. Analysts expect Carisma Therapeutics to post earnings of ($0.1474) per share and revenue of $4.2290 million for the quarter.

Carisma Therapeutics Price Performance

Shares of CARM traded down $0.00 during midday trading on Wednesday, reaching $0.03. The stock had a trading volume of 61,089 shares, compared to its average volume of 113,026. The company has a market capitalization of $1.44 million, a P/E ratio of 0.05 and a beta of 1.86. The firm’s 50 day moving average price is $0.04 and its 200-day moving average price is $0.09. Carisma Therapeutics has a 52 week low of $0.03 and a 52 week high of $1.27.

Institutional Investors Weigh In On Carisma Therapeutics

A hedge fund recently bought a new stake in Carisma Therapeutics stock. Jane Street Group LLC purchased a new stake in Carisma Therapeutics Inc. (NASDAQ:CARM – Free Report) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 150,810 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned about 0.36% of Carisma Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 44.27% of the company’s stock.

About Carisma Therapeutics

(Get Free Report)

Carisma Therapeutics, Inc is a clinical-stage biotechnology company headquartered in the United States that focuses on harnessing the innate immune system to treat cancer and inflammatory diseases. Through its proprietary CARMA (Chimeric Antigen Receptor Macrophage) platform, Carisma engineers macrophages and other myeloid cells to seek out, engulf and destroy diseased cells while reprogramming the surrounding microenvironment. This approach aims to address key limitations of existing T-cell therapies by leveraging the unique trafficking and immunomodulatory properties of innate immune cells.

The company’s lead oncology candidate, CT-0508, employs a HER2-targeted CAR expressed on macrophages to infiltrate and remodel HER2-positive solid tumors.